References

10.1161/circulationaha.120.050686

10.1161/circulationaha.120.050686 · External reference

10.1681/asn.2014070714

10.1681/asn.2014070714 · External reference

10.1161/cir.0000000000001184

10.1161/cir.0000000000001184 · External reference

10.1001/jama.2024.6892

10.1001/jama.2024.6892 · External reference

10.1161/circulationaha.123.067626

10.1161/circulationaha.123.067626 · External reference

10.1161/circulationaha.126.080897

10.1161/circulationaha.126.080897 · External reference

10.1161/circulationaha.124.069568

10.1161/circulationaha.124.069568 · External reference

10.1016/j.ajpc.2024.100679

10.1016/j.ajpc.2024.100679 · External reference

Efficacy and safety of SGLT2 inhibitors with and without glucagon-like peptide 1 receptor agonists: a SMART-C collaborative meta-analysis of randomised controlled trials

10.1016/s2213-8587(24)00155-4 · 2024 · External reference

Structural selectivity of human SGLT inhibitors

10.1152/ajpcell.00328.2011 · 2012 · External reference

Metabolic, Intestinal, and Cardiovascular Effects of Sotagliflozin Compared With Empagliflozin in Patients With Type 2 Diabetes: A Randomized, Double-Blind Study

10.2337/dc21-2166 · 2022 · External reference

10.1016/j.jacc.2018.07.061

10.1016/j.jacc.2018.07.061 · External reference

10.1056/nejmoa2030186

10.1056/nejmoa2030186 · External reference

Effect of sotagliflozin on major adverse cardiovascular events: a prespecified secondary analysis of the SCORED randomised trial

10.1016/s2213-8587(24)00362-0 · 2025 · External reference

10.1016/j.jlr.2026.100975

10.1016/j.jlr.2026.100975 · External reference

10.1074/jbc.ra117.000559

10.1074/jbc.ra117.000559 · External reference

10.1074/jbc.ra120.014095

10.1074/jbc.ra120.014095 · External reference

Metabolomic Profiling of Arginine Metabolome Links Altered Methylation to Chronic Kidney Disease Accelerated Atherosclerosis

2015 · External reference

10.1161/res.0000000000000169

10.1161/res.0000000000000169 · External reference

SGLT2 inhibition protects kidney function by SAM-dependent epigenetic repression of inflammatory genes under metabolic stress

10.1172/jci188933 · 2025 · External reference

10.1172/jci.insight.123130

10.1172/jci.insight.123130 · External reference

10.1161/circulationaha.122.061732

10.1161/circulationaha.122.061732 · External reference

10.1001/jama.2025.20834

10.1001/jama.2025.20834 · External reference

The Sweet Pee model for Sglt2 mutation

10.1681/asn.2010080888 · 2011 · External reference

Empagliflozin reverses obesity and insulin resistance through fat browning and alternative macrophage activation in mice fed a high-fat diet

2019 · External reference

10.2337/db15-1356

10.2337/db15-1356 · External reference

10.1111/j.1432-1033.1997.00001.x

10.1111/j.1432-1033.1997.00001.x · External reference

Continuous fatty acid oxidation and reduced fat storage in mice lacking acetyl-CoA carboxylase 2

10.1126/science.1056843 · 2001 · External reference

Triglycerides and cardiovascular disease

10.1016/s0140-6736(14)61177-6 · 2014 · External reference

10.1161/circresaha.126.327361

10.1161/circresaha.126.327361 · External reference

10.1681/asn.2017030350

10.1681/asn.2017030350 · External reference

Plasma acylcarnitine profiling reveals heart failure-specific fatty acid oxidation signature in chronic kidney disease

10.1016/j.jlr.2026.101072 · 2026 · External reference

10.1038/nm.3804

10.1038/nm.3804 · External reference

Effect of pharmacological selectivity of SGLT2 inhibitors on cardiovascular outcomes in patients with type 2 diabetes: a meta-analysis

10.1038/s41598-024-52331-w · 2024 · External reference

10.2337/db11-1029

10.2337/db11-1029 · External reference

Cardiovascular events and all-cause mortality in patients with type 2 diabetes treated with dipeptidyl peptidase-4 inhibitors: An extensive meta-analysis of randomized controlled trials. Nutrition

10.1016/j.numecd.2021.06.002 · 2021 · External reference